Navigation Links
Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials

PHILADELPHIA and LONDON, Dec. 15 /PRNewswire/ -- Thomson Reuters today announced that Thomson Pharma® has become the first drug pipeline database to fully integrate detailed clinical trial protocol and outcome information. This highly anticipated new content is being provided to all Thomson Pharma customers this month.

Thomson Pharma will offer drug related clinical trial intelligence from registries, publications, press releases, conferences, and other sources across all therapeutic areas. It includes some of the most advanced searching capabilities on the market, enabling identification of trials based on over twenty criteria that are individually indexed by experts. This includes not only trial criteria such as drug, phase and recruitment status, but also scientific criteria such as mechanism of action, target and biomarker.

"We are proud to be the first to integrate drug pipeline content with robust clinical trial content in a single competitive intelligence solution," said Wendy Hamilton, vice president of product strategy at Thomson Reuters. "This not only addresses our customers' needs for increased efficiency and new competitive insights, but also ensures that Thomson Pharma will remain the most comprehensive single solution for pharmaceutical competitive intelligence on the market."

Thomson Pharma covers the entire drug discovery and development pipeline -- the drugs, compounds, targets, companies, clinical trials, patents, journals, conferences, academic articles and more. For more information, please visit:

Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people and operates in over 100 countries. Thomson Reuters shares are listed on the Toronto Stock Exchange (TSX: TRI) and New York Stock Exchange ( TRI). For more information, go to

SOURCE Thomson Reuters

SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Chinas Research Output More Than Doubled Since 2004, Thomson Reuters Study Reveals
2. Thomson Reuters Explores the Opportunities and Challenges of Entering the Japanese Generic Drug Market
3. Thomson Reuters Predicts Nobel Laureates
4. Thomson Joins Brooks Kushman; Strengthens Los Angeles Presence
5. Transcept Pharmaceuticals to Present at the BioCentury Thomson Reuters Newsmakers in the Biotech Industry Conference on September 16, 2009
6. Thomson Reuters Joins the InChI Trust
7. Thomson Reuters Announces 2009 Edition of the CMR International Pharmaceutical R&D Factbook
8. Thomson Reuters Partners With Sagient Research
9. Brazils Scientific Research On The Rise, Thomson Reuters Study Finds
10. Thomson Reuters Makes Disease Briefing on Influenza Covering H1N1 (Swine Flu) Publicly Available
11. Thomson Reuters Examines Highly Cited Research in Bioterrorism
Post Your Comments:
(Date:6/27/2016)... GUELPH, ON , June 27, 2016 /PRNewswire/ - BIOREM ... it has been advised by its major shareholders, Clean ... LP, United States based venture ... common shares of Biorem (on a fully diluted, as ... for the disposition of their entire equity holdings in ...
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
Breaking Biology Technology:
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
Breaking Biology News(10 mins):